key: cord-0838839-ddwp70wl authors: Lattman, E.; Bhalerao, P.; BL, S.; Nargundkar, N.; Lattmann, P.; Pillai K, S.; Balaram, P. N. title: Randomized, Comparative, Clinical Trial to Evaluate Efficacy and Safety of PNB001 in Moderate COVID-19 Patients date: 2021-04-16 journal: nan DOI: 10.1101/2021.04.16.21255256 sha: 1678e913ad0d21581bca9f9464b32ac0ab791098 doc_id: 838839 cord_uid: ddwp70wl Objective: To evaluate the efficacy and safety of PNB001 a CCK-A agonist and CCK-B antagonist, a new chemical entity with anti-inflammatory and immune stimulation properties, along with Standard of Care (SOC) in patients with moderate COVID-19 infection. Design: Multi-center, randomized, parallel group, comparative, open label study. Setting: Two tertiary-care hospitals in India. Participants: Patients with laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain reaction (PCR) within 2 days of randomization, having pneumonia with no signs of severe disease (severe disease means SpO2<=94% on room air), and any two of the following signs or symptoms suggestive of COVID-19: fever, cough, dyspnea, or hypoxia. Interventions: Patients were randomized 1:1 to receive PNB001 at an oral dose of 100 mg three times daily for 14 days with Standard of Care (PNB001+SOC) or only SOC. Main outcome measures: The primary endpoints were mean change in the 8-point WHO Ordinal Scale score from baseline by Day 14 and mortality rate by Day 28. The key secondary endpoints were percentage of patients showing change in clinical status using the ordinal scale, improvement in inflammatory segments in X-ray chest, reduction of days of hospitalization, duration of supplemental oxygen use, days to negative PCR for COVID-19 and change in inflammation markers Interlukin-6 (IL6) and C-reactive protein (CRP) from baseline by Day 14. Results: A total of 40 (20 in PNB 001+SOC arm and 20 in SOC arm) patients were randomized and received treatment. The primary endpoint showed significant clinical improvement from baseline to Day 14 with PNB001+SOC (0.22 Vs 1.12; P=0.0421). One patient in PNB001+SOC arm and two patients in SOC arm died (1 Vs 2; HR: 2.0 [95%CI=0.18, 22.05]; P=0.5637) by Day 28. At the end of the treatment by Day 14, more patients achieved zero ordinal scale in PNB001+SOC arm (17 Vs 12; P=0.0766). In the PNB001+SOC arm, change in mean chest X-ray score showed significant improvement (2.05 Vs 1.16; P=0.0321), and more patients quickly showed complete improvement (10 Vs 7; HR: 1.48 [95%CI=0.64, 3.44]; P=0.4309). In the PNB001+SOC arm, patients needed shorter duration of hospitalization in days (9.45 Vs 9.80) and more patients attained earlier discharge from the hospital (19 Vs 15; P=0.0486) with respect to days. The mean duration of supplemental oxygen requirement in days was shorter (5.45 Vs 7.10) and complete withdrawal from supplemental oxygen was more frequent with PNB001+SOC compared to SOC by Day 14 (17 Vs 13; P=0.1441). All patients in both the arms had negative PCR by the end of the study (18 Vs 17; P=0.6265) by similar time (7.6 Vs 7.0). Exploratory analysis done for IL-6, CRP, Neutrophil-Lymphocyte-Ratio (NLR), Platelet-Lymphocyte-Ratio (PLR) and Erythrocyte Sedimentation Rate (ESR) showed statistically significant reduction by Day 14 demonstrating PNB001's anti-inflammatory and immunomodulatory properties. Lymphocyte and neutrophil counts also improved by Day 14. 11 adverse events (AE) in 8 patients were observed with PNB001+SOC compared to 13 AEs in 10 patients with SOC; none of the AEs in PNB001+SOC arm were related to PNB001. The most common AE were tachycardia and acute respiratory distress syndrome; there were isolated cases of hepatic enzyme elevation and hyperglycemia. Overall, safety profile was similar between PNB001+SOC and SOC arms. Conclusions: PNB001 with standard of care showed significant clinical improvement in moderate COVID-19 patients when compared to standard of care and was well tolerated by moderate COVID-19 patients. Coronavirus disease 2019 has widely spread over the globe since its first case in December 2019 in Wuhan, China. COVID-19 is declared as a pandemic by the WHO. 1 COVID-19 is spread via droplets or direct contact and infects the respiratory tract resulting in pneumonia in most of the cases and acute respiratory distress syndrome (ARDS) in about 15% of the cases. 2 During COVID-19 infection, a large amount of pro-inflammatory cytokines gets released resulting in an aggressive inflammatory response. The event of gust of pro-inflammatory cytokines is known as "cytokine storm", and it shows a direct relation with the increased mortality in COVID-19. 2 High levels of IL-6, C-reactive protein (CRP), neutrophil-Lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), erythrocyte-lymphocyte ratio (ESR), and ferritin are associated with more severe disease. [3] [4] [5] [6] [7] [8] [9] [10] Excessive pro-inflammatory cytokines aggravates ARDS and cause tissue damage leading to multiple organ failure, and unfavorably affect prognosis of severe COVID-19. Severe COVID-19 patients develop cytokine storm syndrome, acute respiratory distress syndrome, organ dysfunction, and death. Neutrophil extracellular traps (NETs) are described as important mediators of tissue damage in inflammatory diseases, and is relevant in COVID-19 pathophysiology. 11 NLR is a predictive biomarker of serious COVID-19 infection. At advanced stage of COVID-19, overproduction of neutrophils via NETosis leads to "cytokine storm", and it is directly linked with high mortality. 2 COVID-19 is an out of tune of the immune system and the main treatment objective is to bring neutrophils and lymphocytes levels back into the healthy range. A therapeutic agent that targets cytokines could improve survival rates and reduce mortality. 2, 10 PNB001, a new chemical entity, is a first in class cholecystokinin-A (CCK-A) agonist and CCK-B antagonist, a unique anti-inflammatory agent with immune stimulation properties. It has shown analgesic, antipyretic and anti-inflammatory properties in animal models. 12, 13 The inflammatory immune response of PNB001 was studied in Dengue infected mice and IL-6 levels were measured. After infection, the levels of pro-inflammatory cytokines were increased until day 3 and levels returned back to normal on week 2 when the virus infection was overcome by the host immune system. PNB001 resulted in a reduction of inflammatory marker IL-6 by 80%, in line with smaller spleen inflammation and a reduced death rate. 14 PNB001 has the potential to reduce the pro-inflammatory cytokines, and in turn the cytokine storm which is the main cause of fatalities in COVID-19 patients. It acts on the inflammatory cytokines by the cholinergic anti-inflammatory pathway and the gastrin-releasing peptide receptor pathway. It is a dual action CCK receptor ligand acting on the CCK-B / gastrin as antagonist and CCK-A agonist. The cholecystokinin via the CCK-2 pathway, reduces inflammation in addition to the CCK-1 cholinergic anti-inflammatory pathway. Figure 1 depicts the role of cholecystokinin in the immune system. In a single ascending dose study, PNB001 was administered under fasting condition. The PK (C max and AUC 0-t ) of PNB001 over the dose range of 25-1500 mg was assessed. 15 In a multiple ascending dose study (50, 100 and 200 mg daily for 14 days), mean half-lives of PNB001 ranged from 2.4 to 6.8 hours on Day 1 and from 5.3 to 7.9 hours on Day 14. 16 PNB001 was well tolerated in both the studies without any incidence of death or serious adverse events. A 100 mg dose was chosen for the next phase of the study. 15, 16 The objectives of this clinical trial were to assess efficacy and safety of PNB001 in combination with standard of care (SOC) in patients with moderate COVID-19 Infection and to compare it with SOC alone. This was a multi-center, randomized, parallel group, comparative, open label, clinical study to evaluate efficacy and safety of PNB001 in patients with moderate COVID-19 infection. The study was conducted in compliance to International Council for Harmonisation (ICH) guidance for Good Clinical Practice (GCP) and CDSCO (Schedule-Y) guidance of New Drugs and Clinical Trials Rules, 2019 (India). The study protocol was approved by independent ethics committee. All the patients provided written informed consent prior to study enrolment. The study was conducted at two sites in India (Study Registration No. CTRI/2020/10/028423). The inclusion criteria of the study were laboratory-confirmed SARS-CoV-2 infection as determined by PCR within 2 days of randomization; patients having pneumonia with no signs of severe disease (severe disease means SpO2 ≤ 94%) on room air; patients with any two of the following signs or symptoms suggestive of COVID-19: fever, cough, dyspnea, or hypoxia; respiratory rate more or equal to 24 per minute; radiographic infiltrates as confirmed by imaging (chest X-ray). Patients were excluded if they required invasive mechanical ventilation; had the following clinically significant laboratory abnormalities: SGOT, SGPT, serum bilirubin > 2. 5 baseline to Day 14. The endpoint -improvement in oxygen saturation from baseline was later removed because when condition of the patient worsened, another mode of oxygen administration was followed, making oxygen saturation comparison, not a useful parameter. Exploratory analysis was done for IL-6, CRP, NLR, PLR, and ESR to assess mean change in these markers from baseline to Day 14. The assessment of safety of PNB001 was based on the frequency of AEs, changes in laboratory values and abnormal vital signs. Safety laboratory parameters were complete blood counts, erythrocytes sedimentation rate, liver function tests, total bilirubin, SGOT, SGPT, serum creatinine, CRP, and IL6 with X-ray Chest and ECG. Vital signs were measured at all visits. Continuous efficacy and safety variables were presented using descriptive statistics which included number, mean, standard deviation, median, and range. Categorical data were presented using counts and percentages. Mean change in the ordinal scale from baseline to end of study was analyzed using paired Wilcoxon signed rank test and 2 sample Wilcoxon rank sum tests. Mortality through Day 28 were analyzed as a time to event endpoint. Differences in time-to-event endpoints by treatment were summarized with Kaplan-Meier curves. Secondary efficacy parameters were analyzed and presented using descriptive statistics. Changes in the inflammatory markers (IL-6, CRP) from baseline to end of study were analyzed using paired Wilcoxon signed rank test and 2 sample Wilcoxon signed rank tests. Exploratory comparative analysis for IL-6, CRP, NLR, PLR and ESR were done within group using paired Wilcoxon rank sum test and between groups using Wilcoxon rank sum test. All the statistical analyses were performed using SAS 9.2 or higher version software. Patients were not involved in the decision of treatment choice, study design, conduct, and interpretation or reporting of results of this study. A total of 42 patients were screened of which one failed during screening and one withdrew consent before randomization. Hence, 40 patients were randomized into two arms, i.e. 20 patients/treatment arm. In PNB001+SOC arm, 18/20 patients completed the study; one patient withdrew consent and one patient was discontinued from the study at the discretion of investigator, as the disease worsened in this patient. In SOC arm, 17/20 patients completed the study; one patient withdrew consent and two patients discontinued from the study at the discretion of investigator as the disease worsened. Thus, total of 35 patients completed the study. The patients whose disease worsened and were discontinued by the investigator, subsequently, succumbed to the disease. Figure 2 depicts the patient disposition flow. There were 14 males in the PNB001+SOC arm and 12 males in the SOC arm. The mean patient age (52.10 years) in PNB001+SOC arm was comparable with (52.8 years) SOC arm. Table 1 ). Two patients in PNB001+SOC arm had history of tobacco use; one was an occasional user and other consumed 10-15 packs of tobacco every week. The concomitant medication usage was comparable between the treatment arms. Commonly used concomitant medication were remdesivir, steroids, heparins, aspirin, different antibiotics, ivermectin, zinc, vitamin C, drugs for acidity, antiemetics, etc. A few patients had comorbid disease such as controlled diabetes mellitus (7), asthma (1), hypertension (6), hypothyroidism (1), deep vein thrombosis (2), pulmonary embolism (1), hyperglycaemia (1) and obesity (1). The baseline characteristics of patients were comparable between the treatment arms (Supplementary Table 1 ). Patients in PNB001+SOC (test) arm showed significant improvement in WHO Ordinal Scale for COVID-19 Clinical Improvement compared to patients in SOC (control) arm at the end of the treatment ( Figure 3 ). Further, patients showed significant Clinical improvement from All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Exploratory analysis done for IL-6, CRP, NLR, PLR and ESR showed statistically significant reduction in values on Day 14 compared to baseline in both the treatment arms demonstrating PNB001's anti-inflammatory and immunomodulatory properties. Patients whose values were within the normal range at the beginning of the study were removed and analysis was performed using the remaining patient data (this was to ensure inclusion of patients who had severe infection alone for comparison). The mean decrease of CRP, IL-6, NLR, PLR, and ESR was larger in PNB001+SOC arm compared to SOC arm and these parameters improved significantly by day 14 with both the treatments. However, there was no statistically significant difference between arms (Supplementary Table 4 ). Figure 4 to 9 depicts effects of PNB001+SOC and SOC on CRP, IL-6, Lymphocyte count, Neutrophil count and glucose level levels. A total of 24 AEs were reported by 18 patients during the study: 11 AEs in 8 patients in PNB001+SOC arm and 13 AEs in 10 patients in SOC arm. The adverse events reported were tachycardia, bradycardia, and hypotension, pain in ear, hyperglycaemia, liver enzymes increased, acute respiratory distress syndrome (ARDS), and bleeding per rectum. The most common AEs were tachycardia (5 in PNB001+SOC arm and 8 in SOC arm) and ARDS (1 in PNB001+SOC arm and 2 in SOC arm). Three AEs of ARDS were severe while all other AEs were mild to moderate in severity; none of the AEs were considered related to the study treatments. One SAE of ARDS reported in PNB001+SOC arm was severe though not related to the study treatment; but that resulted in the death of the patient. The death in PNB001 plus standard of care arm was not considered as related to the study treatment. No clinically significant laboratory abnormality was detected during the study other than an instance of liver enzyme abnormality and another instance of hyperglycaemia documented as adverse event. During vitals assessment, a few events of tachycardia and increased respiratory rate were observed; these events are recorded as AEs. Overall, there was no clinically meaningful difference in the safety profile between PNB001+SOC and SOC arms. The current COVID-19 pandemic compelled the healthcare industry and other stake-holders to congregate sources to evaluate novel or existing therapeutic intervention for the treatment of COVID-19. The efforts of pharmaceutical companies coalition are swiftly and decisively All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. progressing to provide promising therapeutics agents as an effective treatment option for prevention and treatment of COVID-19. WHO recommends that a randomized controlled trials in combination with supportive care is the suitable way to evaluate the efficacy and safety of treatments for COVID- 19. 17 This randomized study was conducted to assess and compare efficacy and safety of PNB001+SOC with SOC. Patients received 100 mg PNB001 three times a day along with standard of care or only standard of care for 14 days. The study efficacy was assessed based on the primary endpoint of WHO Ordinal Scale for COVID-19 Clinical Improvement besides mortality rate. 18 The secondary endpoints were the standard endpoints as recommended by WHO and by Natanegara et al. 18, 19 The patient's demographics, baseline characteristics, and disease severity were comparable between PNB001+SOC and SOC arms. Total three patients (1 in PNB001+SOC arm and 2 in the SOC arm) died during the study; these patients were withdrawn from the study as per the protocol due to worsening of clinical condition prior to the event. The patient who died following randomization to PNB001+SOC is unlikely to have derived benefit from test treatment as half-life of PNB001 is closer to 8 hrs and steady state blood level attainment and pharmacodynamic benefit may require additional days. The secondary efficacy endpoints, mean Chest X-ray score and time to discharge from the hospital showed statistically significant difference favoring PNB001+SOC arm while other secondary endpoints like number of patients achieving zero ordinal scale, number of patients All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. showing complete Chest X-ray improvement, duration of hospitalization, duration of supplemental oxygen requirement and number of patients who could be totally withdrawn from supplemental oxygen showed more quantifiable improvement in PNB001+SOC arm compared to SOC arm. Days to negative PCR at the end of the study was similar in both the arms. Improvement in oxygen saturation from baseline was planned as an endpoint; however, when oxygen saturation worsened in patients, a more efficient oxygen delivery method was employed making the endpoint less meaningful. Due to the increased inflammatory processes, NLR and PLR are elevated in COVID-19 patients. 22 Persistently elevated level of IL-6, ESR, and CRP have been reported in earlier, in severe cases of corona-infected patients. 23 In the current study, IL6, CRP, NLR, PLR, and ESR were significantly reduced from baseline to Day 14 in both the treatment arm. The reduction in these inflammatory markers was higher in the PNB001+SOC arm compared to SOC arm demonstrating anti-inflammatory and immunomodulatory properties of PNB001; however, the difference between the treatment arms were not significant. Recent studies on COVID-19 reported NLR as an independent risk factor of the in-hospital death and a significant prognostic biomarker of outcomes in critically ill patients. 24 In recent years, the bidirectional relationship between the nervous and immune system has become increasingly clear, and its role in both homeostasis and inflammation has been well documented. 25 Since the introduction of the cholinergic anti-inflammatory pathway, there has been an increased interest in parasympathetic regulation of both innate and adaptive immune responses, including T helper 2 responses. PNB001 was originally developed for IBD and the link between IBD and immune system is featured. 26 In vitro, we have shown the release of acetyl choline and acetyl choline regulates immunity. 27 The subtypes of CCK receptors were discussed and in particular the role of CCK-1, CCK and ACH gives insight in to this. CCK1 receptor activation stimulates vagovagal reflex pathways in the brain stem. 28 The cholinergic anti-inflammatory pathway, is the pathway known to modulate cytokine release. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. MIP1β, PDGFB, TNF-α, and VEGFA and we consider these cytokines a result of neutrophil overpopulation, NETosis. PNB001 has the potential to reduce the pro-inflammatory cytokines if values are high and to increase cytokines when low measured in form of IL-6 when required to stimulate lymphocyte production. Currently the in-depth analysis of more lymphocytes is performed to understand, if T cells or B cells are formed and which T cells are formed in particular to help fighting the infection. PNB001 acts by stimulation of the immune response indirectly preventing the cytokine storm, which is the main cause of fatality in COVID-19 patients. 29, 30 In the current study, immune inflammatory marker IL-6 was modulated, reduced when too high and increased when low to stimulate to fight of the immune system. The number of lymphocytes is increased and the number of T cells, monitored in form of CD4/CD8 ratio and these results will be reported in due course. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This randomized clinical study assessed the comparative efficacy and safety PNB001+SOC versus SOC using comprehensive clinical endpoints in moderate COVID-19 patients. We consider that our findings are of high significance as the screened patients underwent randomization, and the baseline characteristics were similar between the treatment arms. All assessed parameters showed significant benefit or favored PNB001+SOC arm. There were a few limitations to the study. The total number of patients enrolled in the study was low, however the number was based on regulatory recommendation during approval. Study was designed as an open label study however since open label was the requirement from the regulatory agency and since endpoints were mostly objective it is unlikely to have biased the endpoint assessment. Three patients (one in treatment and two in control) had to be discontinued due to worsening of clinical condition while another 2 withdrew after randomization into the study, however, this was essential to comply with the protocol. PNB001 with standard of care showed significant clinical improvement in moderate COVID-19 patients when compared to standard of care. PNB001 was well tolerated by moderate COVID-19 patients. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. • Release of large amount of pro-inflammatory cytokines results in an aggressive acute respiratory distress syndrome, causing tissue damage leading to multiple organ failure, and unfavourably affecting prognosis of severe COVID-19. • The NLR ratio is a predictive biomarker for COVID-19 infection. • PNB001 is first in class potent CCK-A agonists and CCK-B antagonist, the unique mechanism of its action being its anti-inflammatory and immune stimulation properties. • PNB001 in combination with standard of care showed significant clinical improvement as assessed by mean change in 8-point WHO ordinal scale when compared to standard of care by Day 14. Primary endpoint of mortality rate and all the secondary endpoints showed quantitatively more benefit with PNB001 • PNB001 100 mg thrice daily along with SOC was well tolerated and showed similar safety profile as the SOC arm. • Anti-inflammatory activity of potent steroids was further improved by PNB001. The NLR, which assess the immune stimulating properties and is the main mechanism to fight COVID19 infection was significantly reduced by PNB001. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (1) Discontinuation at investigator's discretion (1) Discontinued (N=3) Consent withdrawal (1) Discontinuation at investigator's discretion (2) Discontinued (N=2) Consent withdrawal (1) Screen Failure (1) All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 16, 2021. A-PNB001+SOC on day 1 and day 15, B-SOC on day 1 and day 15. CRP was reduced in adjunct group by >90% and less than 80% in the best care group. The decrease was larger than the decrease anticipated with any known anti-inflammatory agent. ESR is an inflammation biomarker at the cellular level and CRP an inflammation biomarker at the molecular level. The reference value for CRP for healthy patients is within the range of 1-5 mg/L. At molecular level of 20 mg/ml, inflammation is classified as mild and at 60 mg/ml as moderate respectively. infections. High IL-6 levels in the hundred range are reduced. For high inflammation a reduction of cytokines is observed. For low IL-6 levels in the single digits the increase is observed, leading to the stimulation of the immune system, via CCK-8, starting the proliferation of lymphocytes. IL-6 is an immune marker. Treatment of cancer and viral infection require a full functioning immune system, prior to COVID hypothesis had been postulated with respect to involvement of the immune system. 31 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 16, 2021. The percentage of neutrophils was reduced from 81% to 65% on adjunct treatment and from 72% to 76% on best care. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Deviations from the protocol were filed and clearly a reduction of glucose blood concentration was found on adjunct treatment. This is of particular importance as pre-diabetic and diabetic patients have a much worse COVID-19 prognosis and are in much higher treatment need All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. P-value (within group) 0.0342 0.0348 * N=19 for SOC arm. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Ear pain 01 (05.00%) 00 (00.00%) Hepatic enzyme increased 01 (05.00%) 00 (00.00%) Hyperglycaemia 01 (05.00%) 00 (00.00%) Acute respiratory distress syndrome 01 (05.00%) 02(10.00%) Asthma 00 (00.00%) 01 (05.00%) Rectal hemorrhage 01 (05.00%) 00 (00.00%) Hypotension 01 (05.00%) 01 (05.00%) All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 16, 2021. ; https://doi.org/10.1101/2021.04.16.21255256 doi: medRxiv preprint COVID-19) Situation Report 52 The COVID-19 Cytokine Storm; What We Know So Far Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes Epidemiological and initial clinical characteristics of patients with family aggregation of COVID-19 High neutrophil to lymphocyte ratio as a prognostic marker in COVID-19 patients Neutrophil to lymphocyte ratio and lymphocyte to C reactive protein ratio in patients with severe coronavirus disease 2019 (COVID 19): A meta analysis Clinical laboratory characteristics in patients with suspected COVID-19: One single-institution experience SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology Cholecystokinin-2/gastrin antagonists: 5-hydroxy-5-aryl-pyrrol-2-ones as anti-inflammatory analgesics for the treatment of inflammatory bowel disease †The authors declare no competing interests. ‡Electronic supplementary information (ESI) available Cannabis, Cannabinoids and Tinnitus PNB Vesper gets DCGI nod to test proprietary drug PNB 001 in COVID-19 patients. Express Pharma A placebo-controlled, randomized, double blind, single ascending dose study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of PNB-001 in healthy adult male subjects A placebo-controlled, randomized, double blind, multiple ascending dose (MAD), multiple cohort, phase I study to assess safety, tolerability, pharmacokinetics of PNB-001 (Baladol) Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults WHO R&D Blueprint: novel Coronavirus COVID-19 Therapeutic Trial Synopsis Statistical Opportunities to Accelerate Development for COVID-19 Therapeutics Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: A single-center cohort study Remdesivir for the Treatment of Covid-19 -Final Report The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients Role of inflammatory markers in corona virus disease (COVID-19) patients: A review Cholinergic Modulation of Type 2 Immune Responses The Enteric Network: Interactions between the Immune and Nervous Systems of the Gut Lymphocyte-derived ACh regulates local innate but not adaptive immunity CCK1-Receptor Stimulation Protects Against Gut Mediator-Induced Lung Damage During Endotoxemia Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents N substituted 5 hydroxy pyrrol 2 ones based cholecystokinin 2 antagonists as experimental anticancer agents for the treatment of lung cancer High neutrophil to lymphocyte ratio as a prognostic marker in COVID-19 patients